Huangzhi Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a multi-marker botanical concentrate manufactured for veterinary pharmaceutical conversion. The product is not a single chemical entity; it is a water-miscible liquid extract standardized by HPLC fingerprint and marker assay, clarified by high-speed centrifugation, and passed through a 0.22 µm membrane. It is supplied under the technical grade code HZOS-VAPI. The material is intended for further pharmaceutical processing: wet granulation binder in tablet manufacture, aqueous phase for injection preparation after isotonicity adjustment and sterilizing filtration, liquid fill or adsorption substrate for capsules, spray-drying or carrier adsorption for powders and granules, premix loading onto feed carriers, and direct dilution for oral solutions. Each use requires dosage-form-specific validation because the neat API carries botanical polysaccharides, polyphenols, and residual electrolytes that influence viscosity, pH, filterability, and heat sensitivity.

What processing differences arise when Huangzhi oral solution API is incorporated into tablets, capsules, and premixes rather than aqueous solutions?

When the liquid concentrate is used as a wet granulation binder, the main processing constraints are solvent load and rheology. In high-shear granulators with impeller speeds of 200 rpm to 400 rpm and chopper speeds of 1500 rpm to 3000 rpm, the API is often diluted 1:1 with purified water to reduce surface tension and prevent localized overwetting. Addition rates below 4 kg/min on a 600 L machine are common; higher rates produce dough-like agglomerates that raise final tablet friability. The wet mass is dried in a fluid-bed dryer at inlet temperature 60 °C to 70 °C until loss on drying is 2.0 % w/w to 4.0 % w/w. For capsule filling, the liquid API is either combined with a viscosity modifier such as hydroxypropyl methylcellulose and filled into hard capsules, or adsorbed onto microcrystalline cellulose and colloidal silicon dioxide at ratios between 1:2 and 1:4 to produce a free-flowing powder. For premixes, the API is sprayed onto feed-grade calcium carbonate or wheat middlings in a ribbon or paddle mixer; mineral-based carriers containing free copper or iron sulfates can discolor the extract and should be replaced with chelated trace mineral forms. The different processes share a common requirement: the liquid is shear-stable, but it should not be exposed to steam injection for prolonged periods because steam can hydrolyze ester-linked marker compounds.

Injection-grade adaptation requires a separate risk assessment because the oral solution API is not automatically suitable for terminal sterilization or aseptic filling. Before use in injection, the diluted solution is filtered through a 0.45 µm prefilter and a 0.22 µm sterilizing-grade membrane. Subvisible particulate matter is evaluated according to USP <788> or Ph. Eur. 2.9.19 on the final formulation, not on the neat concentrate; the concentrate itself is not an injectable solution. Bacterial endotoxin testing is performed by Limulus amebocyte lysate assay according to Ph. Eur. 2.6.14 or USP <85>, with limits derived from target species maximum dose rather than generic water limits. Osmolality and pH are adjusted after dilution because botanical acids can depress pH to 4.0 or lower, which may cause pain on injection in cattle and swine. Terminal sterilization by autoclaving at 121 °C for 15 min may be acceptable only after thermal stability of marker compounds is confirmed; if degradation exceeds 5 %, aseptic filtration is the preferred manufacturing route.

Test methodology and batchwise specification for the oral solution grade

The specification profile is method-driven rather than a single invariant number because the concentrate may be diluted or fortified during manufacture. The following table lists the quality attributes and reference methods; batch-specific limits are supplied on the certificate of analysis. The methods are selected to satisfy GMP requirements for veterinary APIs and to support dosage-form validation.

When residual plant polysaccharides are carried into aqueous injection or oral drench systems, viscosity and filtration capacity become limiting

The concentrate contains water-soluble polysaccharides that increase dynamic viscosity when diluted at cold temperatures. At 20 °C the neat concentrate may exhibit viscosities above 100 mPa·s, while a 1:5 aqueous dilution may fall below 10 mPa·s; however, low-molecular-weight marker compounds and high-molecular-weight polysaccharides do not distribute equally across filter types. Sterilizing-grade membranes with polyethersulfone or polyvinylidene fluoride chemistry have lower protein-binding tendencies and are preferred over nylon membranes. Filtration capacity is commonly reduced when the product is cold-stored or when pH is adjusted upward without adequate mixing, because localized alkaline zones can precipitate polyphenol-metal complexes. In tank-based compounding, a 1.0 µm depth filter followed by a 0.45 µm cartridge is recommended before final sterilizing filtration. In oral drench production, the API is diluted with purified water and mixed for 20 min to 30 min in a stainless steel vessel with a bottom-mounted propeller; high-shear homogenization is not required and may produce stable foam that interferes with filling line level sensors.

Powder and granule conversion can be achieved by adsorption or spray drying. Adsorption onto colloidal silicon dioxide at 1:3 w/w produces a free-flowing powder with angle of repose below 35° when the addition is performed in a ploughshare mixer at 150 rpm for 10 min. Spray drying of the diluted API with maltodextrin DE 10–15 is feasible but requires inlet temperature below 170 °C to prevent marker loss; outlet temperature should be kept below 80 °C. The spray-dried intermediate shows hygroscopicity and should be stored with desiccant in aluminum-laminated bags.

The primary difference between Huangzhi oral solution API and unprocessed herbal powders is the degree of downstream processing. Native herb powders contain intact cell wall material, insoluble starch, and high microbial load; they cannot be used directly in injectable formulations and they degrade tablet hardness by interfering with particle bonding. The oral solution API is membrane-filtered, tested for microbial limits, and standardized by marker assay; however, it is not a single chemical entity. Compared with simple ethanol tinctures, the oral solution grade is water-miscible and can be incorporated into wet granulation and aqueous injection vehicles without introducing ethanol residues that require Class 3 residual solvent control. Compared with spray-dried extracts, the liquid API avoids the thermal degradation and agglomeration that can occur during spray drying, but it is heavier to transport and requires controlled storage. The following table summarizes key differences relevant to formulation selection.

Thermal and chemical constraints govern multi-dosage-form conversion

The API should be stored in closed high-density polyethylene drums at 15 °C to 25 °C, protected from direct sunlight. After opening, the headspace should be flushed with nitrogen if the certificate of analysis indicates oxidative marker loss greater than 2 % over 30 days. The concentrate should not be mixed with strong oxidizing agents, concentrated mineral acids, or cationic surfactants such as benzalkonium chloride without a compatibility study because polyphenolic constituents can form insoluble complexes. Avoid combining the API with aluminum or uncoated mild steel piping for extended holding periods; 316L stainless steel, polypropylene, high-density polyethylene, and glass-lined vessels are acceptable contact materials. In powder adsorption operations, the relative humidity should be controlled below 45 % RH to prevent hygroscopic clumping on maltodextrin carriers. If the API is used in premixes with high levels of copper sulfate or ferrous sulfate, oxidation-reduction reactions can darken the premix and reduce marker recovery during assay; chelated or coated trace mineral sources are preferred. For tablet film coating, the API is not used as a coating liquid; its role is in the core granulation.

The model designation HZOS-VAPI is not a single approved drug product; it identifies the veterinary-grade API intermediate. Quantities are typically supplied in 20 L or 200 L HDPE drums, with tamper-evident closures and batch certificates. The API is manufactured under GMP conditions, but the terminal dosage form is the responsibility of the marketing authorization holder. For purchasing specifications, the CoA should list the active marker content, solvent system, pH, density, and microbial results. Different dosage forms may require different minimum marker content, so the API may be offered as a concentrated form for dilution or as a standardized form ready for direct compounding. Because published data for this specific configuration is limited, compatibility and stability studies should be performed under Good Laboratory Practice conditions before scale-up.

On production-scale liquid filling lines, foam generation is the main operational bottleneck. A rotary piston filler with positive displacement heads performs better than gravity filler because small changes in surface tension cause meniscus variation. The API diluted to 1:10 can be filled into HDPE bottles at 40 °C to reduce viscosity; however, heating above 50 °C may promote precipitation if the solution contains divalent ions from water hardness, so purified water is used. For target-species oral solutions, the concentrated API is diluted in purified water, optionally with a non-reducing sugar or artificial sweetener for palatability masking in swine and poultry. For injectable formulations, the diluted solution is buffered to a physiologically compatible pH, adjusted for isotonicity with sodium chloride, and filtered through a 0.22 µm sterilizing-grade membrane. In capsule development, the liquid may be filled directly into hard capsules with a sealing band to prevent leakage, or converted to a powder by adsorption. In granules and premixes, the API is applied by spray nozzle at pressures between 1.0 bar and 3.0 bar to achieve a droplet size of 150 µm to 300 µm, which improves distribution without forming mud-like agglomerates. Each final dosage form must be validated for marker content, dissolution or release profile, and stability under ICH climatic zones applicable to the target market. The neat oral solution API is not administered directly to animals; it is an intermediate pharmaceutical ingredient.